These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 141123)

  • 41. Chimerism and tolerance in rat recipients of intestinal allografts from ALS-treated donors with and without adjunct naïve-donor-strain bone-marrow cells.
    Nakao A; Nalesnik MA; Ishikawa T; Azhipa O; Demetris AJ; Murase N
    Transplantation; 2003 May; 75(9):1575-81. PubMed ID: 12792518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppressed cellular cytotoxic response in rats bearing skin implants in the anterior chamber of the eye.
    Grogan JB
    Invest Ophthalmol Vis Sci; 1987 Aug; 28(8):1390-6. PubMed ID: 3301732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Host immunosuppression following orthotopic bowel allotransplantation in rats using low-dose cyclosporine.
    Grogan JB; Shimazu R; Masaki Y; Raju S
    Transplant Proc; 1991 Feb; 23(1 Pt 1):870-2. PubMed ID: 1825006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and in vivo immunosuppressive activity of amniotic fluid in the rat.
    Matsui S; Yoshimura N; Oka T
    Transplant Proc; 1989 Apr; 21(2):3307-8. PubMed ID: 2523607
    [No Abstract]   [Full Text] [Related]  

  • 45. In vivo activity of mixed lymphocyte response-generated suppressor cells and ability to prolong cardiac allograft survival in rats.
    Turka LA; Tanaka K; Kupiec-Weglinski JW; Milford EL; Tilney NL; Carpenter CB
    Transplantation; 1989 Feb; 47(2):388-90. PubMed ID: 2521965
    [No Abstract]   [Full Text] [Related]  

  • 46. Augmentation of suppression in cyclophosphamide-treated rats bearing allogeneic skin implants in the anterior chamber of the eye.
    Grogan JB; Subba Rao DS; Henry SE
    Invest Ophthalmol Vis Sci; 1985 Sep; 26(9):1230-5. PubMed ID: 3897115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenolic nortriterpene demethylzeylasteral: a new immunosuppressive component of Tripterygium Wilfordii Hook f.
    Tamaki T; Kawamura A; Komatsu Y; Kawamura H; Maruyama H; Morota T
    Transplant Proc; 1996 Jun; 28(3):1379-80. PubMed ID: 8658703
    [No Abstract]   [Full Text] [Related]  

  • 48. Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate.
    Tran HS; Malli D; Chrzanowski FA; Puc MM; Matthews MS; Hewitt CW
    J Surg Res; 1999 May; 83(2):136-40. PubMed ID: 10329107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence of cell-mediated cytotoxicity and serum blocking activity in highly tolerant rats.
    Wright PW; Bernstein ID; Hamilton B; Hellström KE
    Transplantation; 1975 May; 19(5):437-41. PubMed ID: 239476
    [No Abstract]   [Full Text] [Related]  

  • 50. Selective elimination of alpha/beta T cells as a model for peripheral T-cell tolerance.
    Dufter C; Terness P; Post S; Thies J; Otto G; Opelz G
    Transplant Proc; 1994 Dec; 26(6):3233-4. PubMed ID: 7998127
    [No Abstract]   [Full Text] [Related]  

  • 51. The effects of serum from hosts inoculated perioperatively with donor lymphocytes via portal vein on cytokine release in vitro.
    Ohsaka Y; Yoshimura N; Hamashima T; Lee CJ; Matsui S; Hirakawa K; Oka T
    Transplant Proc; 1991 Feb; 23(1 Pt 1):559-60. PubMed ID: 1824991
    [No Abstract]   [Full Text] [Related]  

  • 52. Testing immunological responses to experimental allografts.
    Hamburger J; Debray-Sachs M; Dimitriu A; Dy M; Caraux J
    Transplant Proc; 1974 Dec; 6(4 Suppl 1):85-91. PubMed ID: 4280168
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunoregulation by antigenic stimulation via the anterior chamber of the eye.
    Rigdon EE; Subba Rao DS; Grogan JB
    J Surg Res; 1982 Nov; 33(5):427-34. PubMed ID: 6752581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Host response to tissues placed in the anterior chamber of the eye: demonstration of migration inhibition factor and serum blocking activity.
    Subba Rao DS; Grogan JB
    Cell Immunol; 1977 Sep; 33(1):125-33. PubMed ID: 332385
    [No Abstract]   [Full Text] [Related]  

  • 55. Studies of tumor implants in immunologically privileged sites.
    Wajsman Z; Williams P; McGarry M; Murphy GP
    J Surg Oncol; 1980; 14(1):73-81. PubMed ID: 6247580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Skin reactions with transplantation antibodies.
    Milgrom F; Gewirtz A; Abeyounis CJ
    Int Arch Allergy Appl Immunol; 1975; 49(1-2):271-5. PubMed ID: 124708
    [No Abstract]   [Full Text] [Related]  

  • 57. Axonal degeneration associated with a defective blood-brain barrier in cerebral implants.
    Svendgaard NA; Björklund A; Hardebo JE; Stenevi U
    Nature; 1975 May; 255(5506):334-6. PubMed ID: 1128693
    [No Abstract]   [Full Text] [Related]  

  • 58. Time and number: the privileged status of small values in the brain.
    Buhusi CV; Cordes S
    Front Integr Neurosci; 2011; 5():67. PubMed ID: 22065383
    [No Abstract]   [Full Text] [Related]  

  • 59. Glial grafting for demyelinating disease.
    Tepavcević V; Blakemore WF
    Philos Trans R Soc Lond B Biol Sci; 2005 Sep; 360(1461):1775-95. PubMed ID: 16147541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tolerance of human fetal retinal pigment epithelium xenografts in monkey retina.
    Berglin L; Gouras P; Sheng Y; Lavid J; Lin PK; Cao H; Kjeldbye H
    Graefes Arch Clin Exp Ophthalmol; 1997 Feb; 235(2):103-10. PubMed ID: 9147949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.